| Literature DB >> 34172895 |
Jean Pegliasco1,2,3, Pierre Hirsch4, Christophe Marzac1,2,5, Françoise Isnard6, Jean-Côme Meniane7, Caroline Deswarte4, Philippe Pellet8, Céline Lemaitre8, Gwendoline Leroy8, Graciela Rabadan Moraes1,9, Hélène Guermouche4, Barbara Schmaltz-Panneau1,2, Florence Pasquier2,3, Chrystelle Colas8,10, Patrick R Benusiglio8, Odile Bera11, Jean-Henri Bourhis3, Eolia Brissot6, Olivier Caron12, Samy Chraibi3, Pascale Cony-Makhoul13, Christine Delaunay-Darivon14, Simona Lapusan6, Flore Sicre de Fontbrune15, Pascal Fuseau11, Albert Najman6, William Vainchenker1,2,16, François Delhommeau4, Jean-Baptiste Micol1,2,3, Isabelle Plo1,2, Christine Bellanné-Chantelot17,18.
Abstract
The germline predisposition associated with the autosomal dominant inheritance of the 14q32 duplication implicating ATG2B/GSKIP genes is characterized by a wide clinical spectrum of myeloid neoplasms. We analyzed 12 asymptomatic carriers and 52 patients aged 18-74 years from six families, by targeted sequencing of 41 genes commonly mutated in myeloid malignancies. We found that 75% of healthy carriers displayed early clonal hematopoiesis mainly driven by TET2 mutations. Molecular landscapes of patients revealed two distinct routes of clonal expansion and leukemogenesis. The first route is characterized by the clonal dominance of myeloproliferative neoplasms (MPN)-driver events associated with TET2 mutations in half of cases and mutations affecting splicing and/or the RAS pathway in one-third of cases, leading to the early development of MPN, mostly essential thrombocythemia, with a high risk of transformation (50% after 10 years). The second route is distinguished by the absence of MPN-driver mutations and leads to AML without prior MPN. These patients mostly harbored a genomic landscape specific to acute myeloid leukemia secondary to myelodysplastic syndrome. An unexpected result was the total absence of DNMT3A mutations in this cohort. Our results suggest that the germline duplication constitutively mimics hematopoiesis aging by favoring TET2 clonal hematopoiesis.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34172895 DOI: 10.1038/s41375-021-01319-w
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 11.528